Search results for " Dual"

showing 10 items of 154 documents

IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition

2017

Abstract The tumor microenvironment supplies proinflammatory cytokines favoring a permissive milieu for cancer cell growth and invasive behavior. Here we show how breast cancer progression is facilitated by IL4 secreted by adipose tissue and estrogen receptor–positive and triple-negative breast cancer cell types. Blocking autocrine and paracrine IL4 signaling with the IL4Rα antagonist IL4DM compromised breast cancer cell proliferation, invasion, and tumor growth by downregulating MAPK pathway activity. IL4DM reduced numbers of CD44+/CD24− cancer stem-like cells and elevated expression of the dual specificity phosphatase DUSP4 by inhibiting NF-κB. Enforced expression of DUSP4 drove conversio…

0301 basic medicineCancer ResearchBlotting WesternCA 15-3Breast Neoplasms03 medical and health sciencesParacrine signalling0302 clinical medicineBreast cancerCell Line TumorTumor MicroenvironmentmedicineHumansskin and connective tissue diseasesAutocrine signallingDual-Specificity PhosphataseBlotting Western; Breast Neoplasms; Cell Line Tumor; Disease Progression; Dual-Specificity Phosphatases; Female; Flow Cytometry; Heterografts; Humans; Interleukin-4; Mitogen-Activated Protein Kinase Phosphatases; Tumor Microenvironment; Oncology; Cancer ResearchTumor microenvironmentbiologyCD44CancerFlow Cytometrymedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyCancer cellDisease Progressionbiology.proteinCancer researchDual-Specificity PhosphatasesHeterograftsMitogen-Activated Protein Kinase PhosphatasesFemaleInterleukin-4HeterograftMitogen-Activated Protein Kinase PhosphataseBreast NeoplasmHumanCancer Research
researchProduct

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

2018

Background The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART). Methods We included patients in Icona who started a three-drug combination ART regimen from an ART-naïve status and achieved a viral load ≤ 50 copies/mL; they were subsequently switched to another triple or to a mono or double regimen. Standard linear regression at fixed points in time (12-24 months after the switch) and linear mixed model analysis with random intercepts and slopes were used to compare CD4 and CD8…

0301 basic medicineMaleCD4-CD8 Ratiolcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Medicine (all)Cohort Studies0302 clinical medicineEmtricitabineHIV Infection030212 general & internal medicineMedicine (all)General MedicineChronic inflammationCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Medicine (all)Middle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaReverse Transcriptase InhibitorReverse Transcriptase InhibitorsFemalecd4/cd8 ratio; cd8; chronic inflammation; dual therapy; monotherapy; medicine (all)Research Articlemedicine.drugCohort studyHumanAdultmedicine.medical_specialtyDual therapyCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; TenofovirAnti-HIV Agents030106 microbiologyCD4-CD8 RatioEmtricitabineSettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesCD4/CD8 ratioInternal medicineLinear regressionmedicineHumansDual therapyTenofovirbusiness.industrylcsh:RAnti-HIV AgentCD8CD8-Positive T-LymphocyteMonotherapyConfidence intervalRegimenCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; MonotherapyCD8; CD4/CD8 ratio; Chronic inflammation; Monotherapy; Dual therapyCohort StudiebusinessCD8
researchProduct

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohor…

2019

Abstract Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 13…

0301 basic medicineMaleHIV Infections0302 clinical medicineDualMedicineHIV InfectionPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyDarunavirCobicistatMiddle AgedViral LoadTolerabilityTolerabilityAnti-Retroviral AgentsCohortMolecular MedicineDrug Therapy CombinationFemaleDarunavir/cobicistatHumanmedicine.drugAdverse eventAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialty030106 microbiologyContext (language use)Durability03 medical and health sciencesDarunavir/cobicistat Dual Durability Tolerability CISAI Adverse eventsVirologyInternal medicineHumansDarunavirbusiness.industryResearchHypertriglyceridemiamedicine.diseaseCISAIDiscontinuationProspective StudieAdverse eventsHIV-1Anti-Retroviral AgentCobicistatbusinesslcsh:RC581-607
researchProduct

Are we correctly measuring the rotational viscosity of heterogeneous bituminous binders?

2020

Modified bituminous binders allow asphalt technologists to design asphalt mixtures with superior performance. However, several recent studies highlighted that due to the complexity of these material, their characterisation can be challenging since common procedures used to characterise neat bitumen might not be adequate. For instance, during high temperature rotational viscosity testing of recycled tyre rubber modified binders (RTR-MB), a number of changes may occur to the sample leading to the here-defined sample stability which in turn provides misleading results. In this study the authors want to first provide a deeper understanding of this phenomenon by a numerical analysis using a besp…

050210 logistics & transportationMaterials science05 social sciences0211 other engineering and technologies02 engineering and technologySample stabilityRheologyAsphaltRotational viscosity021105 building & construction0502 economics and businessCFD dual helical ribbon modified bitumen rheology sample stability recycled tyre rubberSettore ICAR/04 - Strade Ferrovie Ed AeroportiComposite materialCivil and Structural Engineering
researchProduct

Theoretical foundations and applications of the Loop-Tree Duality in Quantum Field Theories

2015

152 páginas. Tesis Doctoral del Departamento de Física Teórica, de la Universidad de Valencia y del Instituto de Física Corpuscular (IFIC).

:FÍSICA [UNESCO]UNESCO::FÍSICAFísica TeóricaQCDLoop-Tree Duality (LTD)
researchProduct

Trastornos de Personalidad: una comparación entre consumidores de heroína, cocaína y alcohol

2004

Objetivos: se analizan la estructura de personalidad y las alteraciones psicológicas que se relacionan con el consumo de sustancias (alcohol, cocaína y heroína).Material y método: Participaron 114 sujetos de los que 46 eran consumidores de alco¬hol, 40 de heroína, y 28 de cocaína. A los sujetos se les aplicó el Inventario Clínico Multiaxial de Millon-II (MCMI-II, 1999).Resultados: Se observa una alta prevalencia de trastornos de personalidad en todos los grupos, el 85% de los sujetos presenta alguno. El 71,4% de los sujetos presenta más de un trastorno. Asimismo se constatan diferentes perfiles de personalidad según la sustancia consumida. Se comprueba mayor prevalencia de trastornos de per…

:PSICOLOGÍA::Psicofarmacología [UNESCO]:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍATrastornos de personalidad Trastorno dual Comorbilidad Drogodependencias Adicciones.UNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Información sobre la evaluación de patología dual en pacientes drogodependientes de Castilla y León

2009

Existe una alta prevalencia de patología dual entre pacientes drogodependientes. El objeto de este estudio es analizar si se ha evaluado o no la patología dual en una muestra de drogodependientes en tratamiento. Se revisaron las historias clínicas de 700 drogodependientes que estaban en tratamiento en 16 Centros de drogodependientes de Castilla y León. El 69% tienen en su historia clínica información sobre la existencia o no de patología dual, el 25,9% está sin información, y el 5,1% en evaluación en el momento de la recogida de datos. La probabilidad de que se haya evaluado la existencia o no de patología dual, es mayor cuando el tratamiento es por el consumo conjunto de heroína+cocaína y …

:PSICOLOGÍA::Psicofarmacología [UNESCO]Comorbilidad psiquiátrica Diagnostico de patología dual Drogodependencia.. Tratamiento en Centros de Drogodependencias.:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Perfil de las usuarias y resultados del tratamiento en régimen residencial mixto de la Comunidad Terapéutica Alborada

2009

La aportación principal de este trabajo con respecto a la perspectiva de género en drogodependencias es generar información sobre la situación y los determinantes de las inequidades de género en el ámbito de los tratamientos residenciales mixtos. Los datos referentes al perfil de las mujeres que realizan tratamiento en nuestra comunidad terapéutica nos permite reflejar la evolución y las necesidades cambiantes, a lo largo de estos últimos cuatro años, en el colectivo de mujeres drogodependientes y la adecuación de nuestra oferta terapéutica a las características específicas observadas.La muestra consta de 42 mujeres que representan el 18,5% de la población que usó el recurso entre el 2005 y…

:PSICOLOGÍA::Psicofarmacología [UNESCO]Comunidad terapéutica drogadicción maternidad patología dual perspectiva de género tratamiento.:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Estudio de caso clínico: diagnóstico dual

2010

El objetivo concreto de nuestro estudio era observar la evolución de los hábitos tóxicos de una paciente con patología dual y, el patrón de consumo en función de su patología mental (trastorno ciclotímico) y de estresores psicosociales. Así mismo esclarecimos los estadios en los que se encontraba y el proceso de cambio que estaba utilizando. También evaluamos su personalidad y su nivel de funcionamiento actual. Todo ello, con el objetivo principal de comprender mejor la comorbilidad entre los trastornos bipolares y los trastornos relacionados con sustancias. La paciente estudiada estaba en seguimiento en la UCA (Unidad de Conductas Adictivas) de Ciudad Real. Para dicho estudio utilizamos la…

:PSICOLOGÍA::Psicofarmacología [UNESCO]Diagnóstico dual personalidad fase de cambio proceso de cambio automedicación tratamiento.:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍAUNESCO::PSICOLOGÍA::Psicofarmacología
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct